Age-Related Macular Degeneration Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

1.1 AMD market will grow significantly during the forecast period, reaching sales of $22.8 billion in 2031
1.2 Development of cell-based and gene therapies represent a new paradigm for AMD
1.3 Reducing treatment burden is an important unmet need for wet AMD
1.4 Treatment for geographic atrophy and dry AMD represent an important unmet need for AMD
1.5 Late-stage pipeline therapies are anticipated to drive growth in the AMD market
1.6 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology
3.2 Classification or staging systems

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.5 Epidemiological forecast for AMD (2021-31)
4.6 Discussion

5.1 Diagnosis and treatment overview
5.2 KOL Insights on Disease Management

6.1 Overview

7.1 Overview
7.2 Longer-acting anti-VEGF therapies
7.3 Treatment for GA
7.4 Availability or accessibility of specialists and patient wait times
7.5 Less invasive drug formulations
7.6 Early diagnosis of patients and increasing awareness of AMD

8.1 Overview
8.2 Clinical trials design

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.2 US
12.3 5EU
12.4 Japan

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.4 Primary research - KOLs interviewed for this report
13.5 Primary research - prescriber survey
13.6 About the authors

• Contact the Publisher

Table 1: AMD: key metrics in the 7MM
Table 2: Biological pathways associated with AMD risk genes
Table 3: The four-stage AREDS classification of AMD
Table 4: Symptoms of AMD
Table 5: Risk factors and comorbid conditions associated with AMD
Table 6: Treatment guidelines for AMD
Table 7: Top 10 deals by value, 2016-21
Table 8: AMD market - global drivers and barriers, 2021-2031
Table 9: Key events impacting sales for AMD in the US, 2021-2031
Table 10: AMD market - drivers and barriers in the US, 2021-2031
Table 11: Key events impacting sales for AMD in the 5EU, 2021-2031
Table 12: AMD market - drivers and barriers in the 5EU, 2021-2031
Table 13: Key events impacting sales for AMD in Japan, 2021-2031
Table 14: AMD market - drivers and barriers in Japan, 2021-2031
Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for AMD in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in AMD during the forecast period
Figure 3: Competitive assessment of recently approved and late-stage pipeline agents that the publisher expects to be licensed for the treatment of wAMD and GA during the forecast period
Figure 4: Comparison of the eye under normal vision and severe vision loss due to AMD
Figure 5: 7MM, total prevalence of AMD, men and women, ages =50 years, %, 2021
Figure 6: 7MM, diagnosed prevalence of AMD, men and women, ages =50 years, 2021
Figure 7: 7MM, sources used and not used to forecast the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD
Figure 8: 7MM, sources used to forecast the total prevalent cases of GA and diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD
Figure 9: 7MM, total prevalent cases of AMD, both sexes, ages =50 years, N, 2021
Figure 10: 7MM, total prevalent cases of AMD by age, both sexes, N, 2021
Figure 11: 7MM, total prevalent cases of AMD, by sex, ages =50 years, N, 2021
Figure 12: 7MM, total prevalent cases of early AMD, both sexes, ages =50 years, N, 2021
Figure 13: 7MM, total prevalent cases of late AMD, both sexes, ages =50 years, N, 2021
Figure 14: 7MM, total prevalent cases of late dry AMD, both sexes, ages =50 years, N, 2021
Figure 15: 7MM, total prevalent cases of late wet AMD, both sexes, ages =50 years, N, 2021
Figure 16: 7MM, total prevalent cases of GA, both sexes, ages =50 years, N, 2021
Figure 17: 7MM, diagnosed prevalent cases of AMD, both sexes, ages =50 years, N, 2021
Figure 18: 7MM, diagnosed prevalent cases of AMD by age, both sexes, N, 2021
Figure 19: 7MM, diagnosed prevalent cases of AMD, by sex, ages =50 years, N, 2021
Figure 20: 7MM, Diagnosed prevalent cases of early AMD, both sexes, ages =50 years, N, 2021
Figure 21: 7MM, diagnosed prevalent cases of late AMD, both sexes, ages =50 years, N, 2021
Figure 22: 7MM, diagnosed prevalent cases of late dry AMD, both sexes, ages =50 years, N, 2021
Figure 23: 7MM, diagnosed prevalent cases of late wet AMD, both sexes, ages =50 years, N, 2021
Figure 24: 7MM, diagnosed prevalent cases of GA, both sexes, ages =50 years, N, 2021
Figure 25: Amsler grid, as viewed by patients with normal vision and with wAMD
Figure 26: Unmet needs and opportunities in AMD
Figure 27: Overview of the development pipeline in AMD
Figure 28: Key late-stage trials for the promising pipeline agents that the publisher expects be licensed for AMD in the 7MM during the forecast period
Figure 29: Competitive assessment of recently approved agents and late-stage pipeline agents that the publisher expects to be licensed for the treatment of wAMD and GA during the forecast period
Figure 30: Competitive assessment of the pipeline drugs benchmarked against the standard of care, Eylea
Figure 31: Analysis of the company portfolio gap in AMD during the forecast period
Figure 32: Global (7MM) sales forecast by country for AMD in 2021 and 2031
Figure 33: Sales forecast by disease subtype for AMD in the US in 2031
Figure 34: Sales forecast for GA in the US in 2031
Figure 35: Sales forecast by class for wAMD in the US in 2021 and 2031
Figure 36: Sales forecast by disease subtype in the 5EU in 2031
Figure 37: Sales forecast by class for wAMD in the 5EU in 2021 and 2031
Figure 38: Sales forecast by class for wAMD in Japan in 2021 and 2031